fordadistrogene movaparvovec

BIOLOGICAL2 trials

Sponsors

Pfizer Inc., Pfizer

Conditions

DUCHENNE MUSCULAR DYSTROPHY (DMD)Duchenne Muscular Dystrophy

Phase 3

A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.

TerminatedNCT05689164

PfizerDuchenne Muscular Dystrophy

Start: 2023-03-13End: 2025-09-24Updated: 2025-10-21

C3391003 - A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Active, not recruitingCTIS2023-508510-42-00

Pfizer Inc.DUCHENNE MUSCULAR DYSTROPHY (DMD)

Start: 2025-03-24Target: 48Updated: 2026-01-20